



**STOCKHOLM, 23 September 2010**

## **Statement on withdrawal of Avandia (rosiglitazone) in Europe from the European Association for the Study of Diabetes (EASD)**

Today the European Medicines Agency (EMA) announced the suspension of the marketing authorisations for the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet, and Avaglin from the market in Europe within the next few months. This decision comes after several years of analysis and controversy regarding the cardiovascular safety of Avandia.

EASD urges patients who are currently taking any of the above medications to contact their medical advisors for advice concerning alternative treatment options.

Patients should be aware that stopping a diabetes medication without consulting a doctor can result in higher levels of blood glucose that may cause serious short term health problems and increase the risk of long-term diabetes-related complications.

Optimal control of glucose, cholesterol and blood pressure is needed in order to limit the risk of long-term complications, and several alternative types of treatment are available to help those with type 2 diabetes achieve these objectives.

**Press enquiries for EASD: [secretariat@easd.org](mailto:secretariat@easd.org)**